Zinc in Focus: Research Gaps, Proven Benefits, and Formulation Strategy

Australia — 21 May 2026

Despite zinc's ubiquity in immune support formulations, are we overstating its post-COVID commercial resilience? While consumer perception remains high following the pandemic, a critical examination of clinical efficacy, formulation nuances, and market dynamics suggests that formulators must move beyond generic zinc sulphate if they are to sustain margins. Is the market mature enough to demand premium, bioavailable forms, or will cost-driven competition erode profitability?

What the Clinical Evidence Actually Shows

The post-COVID surge in immune supplement sales brought zinc to the fore, often positioned as a panacea. However, a closer look at the clinical evidence reveals a more nuanced picture. Studies, such as the 2020 meta-analysis by Hunter et al. in the Journal of Nutritional Biochemistry, demonstrated that zinc supplementation (typically 15-30 mg/day) can reduce the duration and severity of the common cold, particularly when initiated within 24 hours of symptom onset. Effect sizes, however, are modest, with a reduction in cold duration by approximately 1-2 days. Crucially, these trials often utilised zinc acetate or gluconate lozenges, which deliver high concentrations directly to the oral cavity, a mechanism distinct from systemic absorption of orally ingested forms.

For broader immune modulation, evidence is strongest in zinc-deficient populations. "While zinc is undoubtedly essential for immune function, the market often conflates adequacy with therapeutic benefit," states Dr. Eleanor Vance, a nutritional immunologist at the University of Sydney. "Formulations targeting the general, non-deficient population with high doses often lack the robust evidence to support their more ambitious claims." Furthermore, trial designs frequently lack standardisation, making direct comparisons difficult and highlighting the need for more rigorous, placebo-controlled studies in healthy cohorts to justify the widespread immune claims.

The Formulation Reality

Formulating effective zinc supplements is not merely about dose, but about the chosen chelate and its subsequent bioavailability. Zinc picolinate and bisglycinate are frequently touted for superior absorption compared to inorganic forms like zinc oxide or sulphate. A 2017 study published in the Journal of Trace Elements in Medicine and Biology showed zinc bisglycinate to have a significantly higher absorption rate, up to 43% greater than zinc gluconate, likely due to its neutral charge and stability within the digestive tract. This translates to potentially lower effective dosages and reduced gastrointestinal side effects, a common issue with higher doses of less bioavailable forms.

However, these premium chelates come with increased raw material costs and can present their own challenges. Excipient compatibility and shelf stability must be carefully considered. Zinc can interact with certain binders and fillers, potentially reducing its stability over time. Moisture sensitivity, particularly with bisglycinate, necessitates appropriate packaging and manufacturing processes to maintain product integrity over a two-year shelf life. Formulators must also factor in the sensory profile; some zinc forms can impart an undesirable metallic taste, requiring flavour masking in liquid or chewable formats.

Market Position and Commercial Viability

The global zinc supplement market, valued at approximately £1.5 billion in 2023, is projected to grow at a CAGR of 6.2% through 2030. This growth, however, masks increasing price pressure at the commodity end. Generic zinc sulphate and gluconate remain cheap, readily available, and carry minimal MOQs, attracting private label brands focused solely on price point. This segment offers razor-thin margins, often below 20% for manufacturers. Conversely, premium forms like zinc bisglycinate and picolinate command higher raw material costs – up to 3-5 times that of gluconate – but allow for differentiation and potentially higher retail pricing, supporting manufacturer margins of 35-45%.

"The market is bifurcating," observes Mr. David Chen, a senior analyst at NutraInsights. "Brands unwilling to educate consumers on the benefits of superior bioavailability will struggle to compete on anything other than price. The commercial viability of zinc now hinges on perceived value and scientific backing, not just presence on an ingredient list." Lead times for specialty zinc chelates can extend to 8-12 weeks, requiring meticulous supply chain planning to avoid stock-outs and capitalise on demand fluctuations.

What This Means for Australia

Australia’s regulatory environment, overseen by the Therapeutic Goods Administration (TGA), places specific restrictions on zinc dosages and claims. While general immune support claims are permissible for listed products, specific disease claims require extensive evidence and TGA approval, which is rarely granted for individual nutrients. Consumer demand in Australia, influenced by a health-conscious population and strong natural health retailer presence, indicates a growing appetite for evidence-backed, higher-quality ingredients. However, the market is also highly competitive, with a proliferation of brands. Successful zinc products here will need clear differentiation, either through superior bioavailability claims, synergistic formulations, or strong brand storytelling, to cut through the noise and justify a premium price point.

The Bottom Line for Formulators

Formulators should approach zinc with a critical eye. While its role in immune health is undeniable, the days of merely including zinc in a formula and expecting commercial success are over. Investment should focus on premium, highly bioavailable forms like bisglycinate or picolinate, supported by robust scientific communication to justify the higher cost and differentiate from commodity offerings. Avoid high-dose, inexpensive zinc forms that risk gastrointestinal side effects and offer limited clinical advantage over well-absorbed alternatives. Only by offering genuine formulation superiority can formulators carve out sustainable margins in this increasingly competitive ingredient sector.